FOLH1 and prostate carcinoma: In the past decade, use of theranostic pairs, targeted to somatostatin receptors (SSTRs) and prostate-specific membrane antigen (PSMA), has significantly altered the treatment paradigm in advanced neuroendocrine tumors (NETs) and prostate cancer (PCa), respectively.